Daiwa Securities Group Inc. Has $21.35 Million Stock Holdings in Repligen Corporation $RGEN

Daiwa Securities Group Inc. raised its holdings in Repligen Corporation (NASDAQ:RGEN) by 154.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 130,277 shares of the biotechnology company’s stock after acquiring an additional 79,039 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Repligen were worth $21,347,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the third quarter valued at approximately $29,000. Bayforest Capital Ltd acquired a new stake in Repligen in the fourth quarter valued at approximately $32,000. Rachor Investment Advisory Services LLC acquired a new stake in Repligen in the fourth quarter valued at approximately $33,000. Farther Finance Advisors LLC lifted its stake in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in Repligen in the third quarter valued at approximately $65,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have issued reports on RGEN shares. UBS Group reduced their target price on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. KeyCorp restated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wells Fargo & Company reduced their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Price Performance

Shares of Repligen stock opened at $122.31 on Friday. The firm has a fifty day simple moving average of $118.67 and a 200-day simple moving average of $138.77. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 1-year low of $100.99 and a 1-year high of $175.77. The stock has a market capitalization of $6.90 billion, a price-to-earnings ratio of 135.90, a PEG ratio of 2.44 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million during the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the previous year, the company earned $0.39 earnings per share. Repligen’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.